172 related articles for article (PubMed ID: 33316767)
21. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma.
Abu-Sbeih H; Ali FS; Qiao W; Lu Y; Patel S; Diab A; Wang Y
Cancer Immunol Immunother; 2019 Apr; 68(4):553-561. PubMed ID: 30666357
[TBL] [Abstract][Full Text] [Related]
22. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management.
Abu-Sbeih H; Ali FS; Wang Y
Curr Opin Gastroenterol; 2020 Jan; 36(1):25-32. PubMed ID: 31609734
[TBL] [Abstract][Full Text] [Related]
23. Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis.
Machado AP; Shatila M; De Toni EN; Török HP; Philpott J; Zhao D; Zhou Y; Varatharajalu K; Shafi MA; Zhang HC; Thomas AS; Wang Y
J Cancer; 2023; 14(14):2686-2693. PubMed ID: 37779873
[No Abstract] [Full Text] [Related]
24. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
25. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
Tandon P; Bourassa-Blanchette S; Bishay K; Parlow S; Laurie SA; McCurdy JD
J Immunother; 2018 Apr; 41(3):101-108. PubMed ID: 29401166
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
27. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis.
Pisuchpen N; Durbin SM; Mooradian MJ; Fintelmann FJ; Reynolds KL; Dougan M; Kambadakone A
Eur Radiol; 2021 Dec; 31(12):8868-8878. PubMed ID: 34081152
[TBL] [Abstract][Full Text] [Related]
28. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
[TBL] [Abstract][Full Text] [Related]
29. Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma?
Bugdayci Basal F; Karacin C; Bilgetekin I; Oksuzoglu OB
Urol Int; 2021; 105(7-8):666-673. PubMed ID: 33730725
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
31. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
Miyashita H; Mikami T; Satoi S; Cruz C; Galsky MD
J Immunother; 2020; 43(9):291-298. PubMed ID: 32960847
[TBL] [Abstract][Full Text] [Related]
32. Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis.
Kaneoka A; Okada E; Sugino H; Saito-Sasaki N; Omoto D; Nakamura M
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204571
[TBL] [Abstract][Full Text] [Related]
33. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.
Assarzadegan N; Montgomery E; Anders RA
Virchows Arch; 2018 Jan; 472(1):125-133. PubMed ID: 29143108
[TBL] [Abstract][Full Text] [Related]
36. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
37. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study.
Massari F; Di Nunno V; Guida A; Costa Silva CA; Derosa L; Mollica V; Colomba E; Brandi G; Albiges L
Clin Genitourin Cancer; 2021 Feb; 19(1):32-40. PubMed ID: 32694008
[TBL] [Abstract][Full Text] [Related]
38. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoint Inhibitors-Induced Colitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
[TBL] [Abstract][Full Text] [Related]
40. Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.
Konishi S; Hatakeyama S; Numakura K; Narita S; Inoue T; Saito M; Tokui N; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Narita S; Kawaguchi T; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2019 Oct; 17(5):e1080-e1089. PubMed ID: 31416753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
